Drug Database
Back to search

Belgium· BE-AMP-SAM663261-00

Spikevax JN.1 50 µg

A covid-19, rna-based vaccine product containing sars-cov-2 jn.1 mrna, registered in Belgium by Moderna Biotech Spain. The same ATC class is registered in 11 of our 19 countries.

ATC J07BN01

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedSpikevax JN.1 50 µgATCJ07BN01REGISTER NO.BE-AMP-SAM663261-00PACKS LISTED0CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sars-cov-2 jn.1 mrnaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Covid-19, rna-based vaccine is registered in 11 of 19 countries.

Countries holding a registration under ATC J07BN01 (covid-19, rna-based vaccine), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search covid-19, rna-based vaccine products by name

Covid-19, rna-based vaccine · ATC J07BN01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
SARS-CoV-2 JN.1 mRNA
Manufacturer
Moderna Biotech Spain
Country
Belgium (BE)
ATC code
J07BN01
ATC class
Covid-19, RNA-based vaccine
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under J07BN01

Covid-19, rna-based vaccine, as other registers publish it.

All covid-19, rna-based vaccine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f71f58d1-698d-4bf1-845c-1e753ff03eeb
GET /v1/drugs/f71f58d1-698d-4bf1-845c-1e753ff03eeb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Dispersion for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Spikevax JN.1 50 µg",
  "name_fr": "Spikevax JN.1 50 µg",
  "name_nl": "Spikevax JN.1 50 µg",
  "amp_code": "SAM663261-00",
  "strengths": [
    "50.0000",
    "50.0000"
  ],
  "pack_count": 2,
  "substances": [
    "SARS-CoV-2 JN.1 mRNA",
    "Sodium Acetate Trihydrate",
    "Sucrose"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Covid-19, RNA-based Vaccine",
  "authorisation_numbers": [
    "EU/1/20/1507/022",
    "EU/1/20/1507/021"
  ]
}
API referenceMCP serverPlans

See everything about covid-19, rna-based vaccine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console